{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Fatty+Liver+Disease&page=4",
    "query": {
      "condition": "Fatty Liver Disease",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 673,
    "total_pages": 68,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Fatty+Liver+Disease&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Fatty+Liver+Disease&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T08:58:48.616Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00274495",
      "title": "Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Hepatitis C Infection",
        "Fatty Liver"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone and Pegasys/Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2006-01",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2007-11-01",
      "last_synced_at": "2026-10-10T08:58:48.616Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00274495"
    },
    {
      "nct_id": "NCT04997486",
      "title": "The Effect of Time-restricted Eating on Liver Metabolism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "NAFLD",
        "Obesity",
        "Nutritional and Metabolic Diseases"
      ],
      "interventions": [
        {
          "name": "Time restricted eating",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "25 Years to 75 Years"
      },
      "enrollment_count": 5,
      "start_date": "2021-07-20",
      "completion_date": "2024-03-07",
      "has_results": false,
      "last_update_posted_date": "2024-11-25",
      "last_synced_at": "2026-10-10T08:58:48.616Z",
      "location_count": 1,
      "location_summary": "Davis, California",
      "locations": [
        {
          "city": "Davis",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04997486"
    },
    {
      "nct_id": "NCT02421094",
      "title": "Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "GR-MD-02",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galectin Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 30,
      "start_date": "2015-09",
      "completion_date": "2016-09-27",
      "has_results": true,
      "last_update_posted_date": "2020-10-08",
      "last_synced_at": "2026-10-10T08:58:48.616Z",
      "location_count": 1,
      "location_summary": "Fort Sam Houston, Texas",
      "locations": [
        {
          "city": "Fort Sam Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02421094"
    },
    {
      "nct_id": "NCT05680233",
      "title": "Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Nonalcoholic Steatohepatitis",
        "Nonalcoholic Fatty Liver"
      ],
      "interventions": [
        {
          "name": "OA-235i (4 mg)",
          "type": "DRUG"
        },
        {
          "name": "OA-235i (8 mg)",
          "type": "DRUG"
        },
        {
          "name": "OA-235i (16 mg)",
          "type": "DRUG"
        },
        {
          "name": "OA-235i (30 mg)",
          "type": "DRUG"
        },
        {
          "name": "OA-235i (40 mg)",
          "type": "DRUG"
        },
        {
          "name": "OA-235i or placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oasis Pharmaceuticals, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 24,
      "start_date": "2023-03-06",
      "completion_date": "2024-07-02",
      "has_results": false,
      "last_update_posted_date": "2025-06-25",
      "last_synced_at": "2026-10-10T08:58:48.616Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05680233"
    },
    {
      "nct_id": "NCT00457938",
      "title": "Novel Therapies for Metabolic Complications of Lipodystrophies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Insulin Resistance",
        "Hypertriglyceridemia",
        "Diabetes",
        "Hepatic Steatosis"
      ],
      "interventions": [
        {
          "name": "low-fat diet ( Still recruiting )",
          "type": "OTHER"
        },
        {
          "name": "Diet",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "14 Years to 70 Years"
      },
      "enrollment_count": 4,
      "start_date": "2006-04",
      "completion_date": "2014-11",
      "has_results": false,
      "last_update_posted_date": "2018-10-16",
      "last_synced_at": "2026-10-10T08:58:48.616Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00457938"
    },
    {
      "nct_id": "NCT03486899",
      "title": "A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver Fibrosis",
        "Nonalcoholic Fatty Liver Disease (NAFLD)",
        "Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "BMS-986036",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 197,
      "start_date": "2018-06-19",
      "completion_date": "2021-08-17",
      "has_results": true,
      "last_update_posted_date": "2022-09-09",
      "last_synced_at": "2026-10-10T08:58:48.616Z",
      "location_count": 83,
      "location_summary": "Madison, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more",
      "locations": [
        {
          "city": "Madison",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03486899"
    },
    {
      "nct_id": "NCT02365233",
      "title": "Fatty Liver Study in Patients With Type II Diabetes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type II Diabetes",
        "Nonalcoholic Fatty Liver"
      ],
      "interventions": [
        {
          "name": "DPP4 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Lantus insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2013-05-01",
      "completion_date": "2016-12-31",
      "has_results": true,
      "last_update_posted_date": "2018-07-31",
      "last_synced_at": "2026-10-10T08:58:48.616Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02365233"
    },
    {
      "nct_id": "NCT02897908",
      "title": "Non-invasive Liver Screening Using FibroScan Device for Liver Disease Patients for the Steatosis/Fibrosis Database",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Disease of Liver and Bile Duct"
      ],
      "interventions": [
        {
          "name": "vibration controlled transient elastography (VCTE)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "State University of New York at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2016-10-28",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-10-10T08:58:48.616Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02897908"
    },
    {
      "nct_id": "NCT05692024",
      "title": "COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Coffee",
        "Gastrointestinal Microbiome",
        "Stenosis",
        "Fibrosis, Liver",
        "Ultrasound Elastography",
        "Proton Magnetic Resonance Spectroscopy"
      ],
      "interventions": [
        {
          "name": "Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule.",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2024-03-21",
      "completion_date": "2028-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-10-10T08:58:48.616Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05692024"
    },
    {
      "nct_id": "NCT02506946",
      "title": "NAFLD in Adolescents and Young Adults With PCOS",
      "overall_status": "SUSPENDED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Polycystic Ovary Syndrome",
        "Non-Alcoholic Fatty Liver Disease",
        "Metabolic Syndrome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "25 Years",
        "sex": "FEMALE",
        "summary": "14 Years to 25 Years · Female only"
      },
      "enrollment_count": 80,
      "start_date": "2013-07",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-10T08:58:48.616Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02506946"
    }
  ]
}